<DOC>
	<DOCNO>NCT00098501</DOCNO>
	<brief_summary>This phase I trial study side effect , best way give , best dose CCI-779 EKB-569 treating patient advance solid tumor . Drugs use chemotherapy , CCI-779 , work different way stop growth tumor cell , either kill cell stop divide . EKB-569 may stop growth tumor cell block enzyme need growth . Giving CCI-779 together EKB-569 may kill tumor cell .</brief_summary>
	<brief_title>CCI-779 EKB-569 Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose combination CCI-779 EKB-569 patient advance solid tumor . II . Determine toxicity regimen patient . III . Determine response rate patient treat regimen . OUTLINE : This dose-escalation study . Patients assign 1 3 treatment group . Group I : Patients receive oral EKB-569 day 1-28 oral CCI-779 day 1-7 15-21 . Cohorts 3-6 patient receive escalate dos EKB-569 CCI-779 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Group II : Patients receive oral EKB-569 MTD day 4-28 course 1 day 1-28 subsequent course CCI-779 MTD day 1-3 15-17 . Group III : Patients receive EKB-569 MTD group I oral CCI-779 MTD day 7-9 19-21 course 1 day 1-3 15-17 subsequent course . In group , course repeat every 28 day absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 30-42 patient ( 18-30 group I , 6 group II , 6 group III ) accrue study within 1.35-1.75 year .</detailed_description>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Histologically confirm unresectable solid tumor know standard therapy potentially curative capable extend life expectancy No CNS metastases Performance status ECOG 02 At least 12 week Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 10 g/dL Bilirubin normal AST ≤ 3 time upper limit normal ( ULN ) ( 5 time ULN liver involvement ) Creatinine ≤ 1.5 time ULN No New York Heart Association class III IV heart disease Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study participation Fasting cholesterol &lt; 350 mg/dL Fasting triglycerides &lt; 400 mg/dL No uncontrolled infection No seizure disorder More 4 week since prior immunotherapy More 4 week since prior biologic therapy No concurrent immunotherapy No concurrent prophylactic colonystimulating factor therapy More 4 week since prior chemotherapy ( 6 week mitomycin nitrosoureas ) recover No concurrent chemotherapy No concurrent oral contraceptive More 4 week since prior radiotherapy No prior radiotherapy &gt; 30 % bone marrow No concurrent radiotherapy More 7 day since prior CYP3A4 inducers No prior mTORtargeting agent No prior epidermal growth factor receptortargeting agent No concurrent antiretroviral therapy induces inhibit CYP3A4 HIVpositive patient No concurrent investigational agent No concurrent warfarin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>